Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains challenging to treat effectively. This study compared the real-world efficacy and safety of three interleukin (IL)-23p19 inhibitors—risankizumab, guselkumab, and tildrakizumab 200 mg—in patients with moderateto-severe plaque ps
Real‑World Efficacy of IL‑23 Inhibitors in Psoriasis Affecting High‑Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis)
Martina Maurelli;Giampiero Girolomoni;
2026-01-01
Abstract
Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains challenging to treat effectively. This study compared the real-world efficacy and safety of three interleukin (IL)-23p19 inhibitors—risankizumab, guselkumab, and tildrakizumab 200 mg—in patients with moderateto-severe plaque ps
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Trovato IL-23i Derm Ther 2026.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
841.07 kB
Formato
Adobe PDF
|
841.07 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
